Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists

The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.

New this week!

EDITOR OF THE MONTH!

Dr. Guillaume Grzych is a Medical Biologist with a specialization in biochemistry, currently serving at the University Hospital of Lille. He holds the position of Associate Professor and Hospital Practitioner, with dual qualifications in Pharmacy (PharmD) and Medicine (PhD). 

Latest Research toward the treatment of NASH disease

Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.

LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS

The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES